Abstract
The use of non-steroidal anti-inflammatory drugs has been associated with a reduced incidence of Alzheimer's disease (AD), suggesting that attenuation of the inflammatory response may be beneficial. Several, but not all, genetic association studies have shown human leucocyte antigen (HLA)-A2, a major histocompatibility complex class I antigen-binding transmembrane protein has an increased frequency in AD compared to controls, and in some reports is associated with a lowered age of onset. We further investigated the role of HLA-A2 in an independent sample of AD cases, including a large early onset cohort. The results of this current study and meta analysis of all studies available to date support previous evidence of an excess of HLA-A2 in AD, but found no evidence of a relationship with age of onset. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 37-40 |
Number of pages | 4 |
Journal | Neuroscience Letters |
Volume | 294 |
Publication status | Published - 2000 |
Keywords
- Alzheimer's disease
- apolipoprotein E
- human leucocyte antigen
- HISTOCOMPATIBILITY ANTIGENS
- HLA-A2 ALLELE
- APOLIPOPROTEIN-E
- ASSOCIATION
- SUSCEPTIBILITY
- GENE
- POLYMORPHISM
- MEN